December 6th 2024
Lilly is investing $3 billion to expand its recently acquired manufacturing facility in Wisconsin, while Amgen is investing $1 billion to expand its facility in North Carolina.
Through the agreement, Cambrex will provide accelerated access to clinical development capabilities to Lilly’s biotech collaborators.
November 23rd 2024
The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.
The $3.6 million investment will allow the CDMO to boost its advanced labeling, automated visual inspection, and fill/finish capabilities.
November 22nd 2024
Sanofi will use this investment to increase its antibody bioproduction at its site in Lyon Gerland, France.
Ricoh and ERS Genomics Enter License Agreement for CRISPR/Cas9 Technology
Ricoh aims to create novel disease models for R&D using ERS Genomics’ CRISPR/Cas9 genome editing technology.
Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease
Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection
J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans
New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.
AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
First in Line on Catalent’s Line
While Catalent’s acquisition is definitely about making drugs, it’s also very much about making money.
Nona Biosciences Partners with Boostimmune on ADC Development
Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.
CSL Licenses Cytegrity Lentiviral Vector Production System to Genezen
CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.
Pharmaceutical Outsourcing Present and Future
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
BioVaxys Acquires Full Portfolio of Former IMV
BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.
Samsung Biologics Partners with LegoChem Biosciences on ADCs
Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.
Novartis to Acquire MorphoSys for Roughly $2.9 Billion
Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.
Novo Holdings to Acquire Catalent in Deal Valued at $16.5 billion
Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.
J.P. Morgan Losing Weight
Given its positioning at each new year’s commencement, the J.P. Morgan Healthcare conference helps establish the tone with which the pharmaceutical industry is viewed.
Regeneron Forms R&D Cell Therapy Unit from 2seventy bio Platform Acquisition
With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.
IMU Biosciences Raises Millions in Series A Funding Round
IMU Biosciences has secured £11.5 million in its Series A financing round.
Sanofi to Aquire Inhibrx for $1.7 Billion
The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.
KBI Biopharma and Argonaut Manufacturing Services Team Up on Drug Substance and Drug Product Manufacturing Solutions
Under a new alliance, KBI Biopharma and Argonaut Manufacturing Services will combine their strengths to offer end-to-end biopharma development and CGMP manufacturing solutions.
Novartis Acquires Calypso Biotech for up to $425 Million
The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.
Bora Pharmaceuticals Fuels Global Expansion with Acquisition in US
The acquisition marks a pivotal expansion for the company into the US market.
Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.
AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development
CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.
Boehringer Ingelheim Expands Facility in Greece for Production of New Therapeutics
Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.
Pluri Launches New Cell Therapy CDMO Division
Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.
Clarivate Highlights 13 Potential Drugs to Watch in Latest Report
Clarivate's Drugs to Watch report highlights 13 potential blockbuster drugs and gamechangers set to launch in 2024.
GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio
In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.
DoD Grants Additional Funds to MediWound for Advancement of Non-Surgical Treatment for Field Care Burns
MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.
Boehringer Ingelheim and Ribo Partner on RNA-based Liver Disease Therapeutics
Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.
Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal
Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.